Page last updated: 2024-12-07

methyl alpha-d-galactopyranoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methyl alpha-D-galactopyranoside, also known as MeαGal, is a simple sugar derivative that has been extensively studied in various fields due to its biological activity and potential applications. It is a synthetic compound, typically obtained through the methylation of alpha-D-galactose. Methyl alpha-D-galactopyranoside has been found to exhibit various biological effects, including inhibition of certain enzymes and modulation of immune responses. Its importance stems from its ability to interact with specific receptors and molecules within biological systems, making it a valuable tool for investigating carbohydrate recognition and binding events. This compound is particularly studied for its potential use in developing novel therapeutic agents, such as anti-inflammatory drugs, anti-cancer agents, and vaccines. Research efforts focus on understanding its interaction with various receptors, exploring its therapeutic applications, and investigating its potential as a probe for studying carbohydrate-mediated processes.'

methyl-galactopyranoside: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methyl alpha-D-galactoside : An alpha-D-galactoside having a methyl substituent at the anomeric position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID76935
CHEMBL ID467773
CHEBI ID55507
SCHEMBL ID505008
MeSH IDM0443387

Synonyms (63)

Synonym
me-alpha-gal
alpha-d-galpome
alpha-methyl d-galactopyranoside
alpha-d-galome
chebi:55507 ,
alpha-methyl d-galactoside
methyl alpha-d-galactoside
mehtyl-a-d-galactopyranoside
bdbm50034081
CHEMBL467773 ,
einecs 222-251-7
esj6uy55qn ,
methyl-galactopyranoside
unii-esj6uy55qn
nsc 33684
3396-99-4
.alpha.-d-galactopyranoside, methyl
nsc-33684
methyl .alpha.-d-galactoside
.alpha.-methyl-d-galactopyranoside
methyl .alpha.-d-galactopyranoside
.alpha.-methyl-d-galactoside
AMG ,
methyl alpha-d-galactopyranoside
methyl alpha-galactoside
DB02100
alpha-methyl-d-galactoside
methyl-alpha-d-galactopyranoside
1-o-methyl-alpha-d-galactopyranoside ,
1-methyl-d-galactopyranoside
methyl-alpha-d-galactoside
a-methyl-d-galactoside
alpha-methylgalactoside
1-o-methyl-alpha-d-galactopyranose
alpha-methyl-d-galactopyranoside
6BD947CC-7166-409C-84AA-2521D81B8BB5
M1047
methyl |a-d-galactopyranoside
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol
AKOS016015049
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-methoxytetrahydro-2h-pyran-3,4,5-triol
EPITOPE ID:150066
AM83974
galactopyranoside, methyl, alpha-d-
galactopyranoside, methyl, .alpha.-d-
methyl .alpha.-galactopyranoside
1-o-methyl-.alpha.-d-galactopyranoside
SCHEMBL505008
mfcd00064085
4NDU
methyl a-d-galactopyranoside
methyl alpha-d-galactopyranoside, purum, >=98.0% (sum of enantiomers, hplc)
methyl alpha-galactopyranoside
DTXSID30187575
DS-6002
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-3,4,5-triol
Q18344140
methyl-a-d-galactopyranoside
methyl | inverted exclamation mark-d-galactopyranoside
D78224
methyl ?-d-galactopyranoside
methyl alpha -d-galactopyranoside
CS-0130438
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
alpha-D-galactosideAny D-galactoside having alpha-configuration at its anomeric centre.
methyl D-galactoside
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Galectin-8Homo sapiens (human)Kd6,300.00002.30002.30002.3000AID1181397
Galectin-3Homo sapiens (human)Kd2,700.00000.15000.22000.2900AID1181395
PA-I galactophilic lectinPseudomonas aeruginosa PAO1Kd20.00000.07100.07100.0710AID1171655
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
regulation of interleukin-4 productionGalectin-9Homo sapiens (human)
regulation of interleukin-5 productionGalectin-9Homo sapiens (human)
toll-like receptor 2 signaling pathwayGalectin-9Homo sapiens (human)
toll-like receptor 4 signaling pathwayGalectin-9Homo sapiens (human)
mature conventional dendritic cell differentiationGalectin-9Homo sapiens (human)
regulation of p38MAPK cascadeGalectin-9Homo sapiens (human)
natural killer cell tolerance inductionGalectin-9Homo sapiens (human)
chemotaxisGalectin-9Homo sapiens (human)
inflammatory responseGalectin-9Homo sapiens (human)
female pregnancyGalectin-9Homo sapiens (human)
positive regulation of gene expressionGalectin-9Homo sapiens (human)
negative regulation of gene expressionGalectin-9Homo sapiens (human)
response to lipopolysaccharideGalectin-9Homo sapiens (human)
negative regulation of chemokine productionGalectin-9Homo sapiens (human)
negative regulation of type II interferon productionGalectin-9Homo sapiens (human)
negative regulation of tumor necrosis factor productionGalectin-9Homo sapiens (human)
positive regulation of type II interferon productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-1 beta productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-10 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-12 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-13 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-4 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-6 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-8 productionGalectin-9Homo sapiens (human)
positive regulation of tumor necrosis factor productionGalectin-9Homo sapiens (human)
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune responseGalectin-9Homo sapiens (human)
p38MAPK cascadeGalectin-9Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGalectin-9Homo sapiens (human)
negative regulation of mast cell degranulationGalectin-9Homo sapiens (human)
negative regulation of natural killer cell mediated cytotoxicityGalectin-9Homo sapiens (human)
negative regulation of activated T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of viral entry into host cellGalectin-9Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityGalectin-9Homo sapiens (human)
maternal process involved in female pregnancyGalectin-9Homo sapiens (human)
positive regulation of activated T cell autonomous cell deathGalectin-9Homo sapiens (human)
ERK1 and ERK2 cascadeGalectin-9Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGalectin-9Homo sapiens (human)
response to interleukin-1Galectin-9Homo sapiens (human)
cellular response to type II interferonGalectin-9Homo sapiens (human)
positive regulation of transforming growth factor beta productionGalectin-9Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionGalectin-9Homo sapiens (human)
cellular response to virusGalectin-9Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionGalectin-9Homo sapiens (human)
positive regulation of dendritic cell chemotaxisGalectin-9Homo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of dendritic cell apoptotic processGalectin-9Homo sapiens (human)
positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellGalectin-9Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-9Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayGalectin-9Homo sapiens (human)
cellular response to virusGalectin-8Homo sapiens (human)
xenophagyGalectin-8Homo sapiens (human)
lymphatic endothelial cell migrationGalectin-8Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-1Homo sapiens (human)
plasma cell differentiationGalectin-1Homo sapiens (human)
apoptotic processGalectin-1Homo sapiens (human)
T cell costimulationGalectin-1Homo sapiens (human)
regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGalectin-1Homo sapiens (human)
myoblast differentiationGalectin-1Homo sapiens (human)
positive regulation of viral entry into host cellGalectin-1Homo sapiens (human)
positive regulation of inflammatory responseGalectin-1Homo sapiens (human)
cell-cell adhesionGalectin-1Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-3Homo sapiens (human)
monocyte chemotaxisGalectin-3Homo sapiens (human)
mRNA processingGalectin-3Homo sapiens (human)
RNA splicingGalectin-3Homo sapiens (human)
neutrophil chemotaxisGalectin-3Homo sapiens (human)
epithelial cell differentiationGalectin-3Homo sapiens (human)
positive regulation of protein-containing complex assemblyGalectin-3Homo sapiens (human)
regulation of T cell proliferationGalectin-3Homo sapiens (human)
innate immune responseGalectin-3Homo sapiens (human)
negative regulation of endocytosisGalectin-3Homo sapiens (human)
eosinophil chemotaxisGalectin-3Homo sapiens (human)
macrophage chemotaxisGalectin-3Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayGalectin-3Homo sapiens (human)
positive chemotaxisGalectin-3Homo sapiens (human)
regulation of T cell apoptotic processGalectin-3Homo sapiens (human)
mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of calcium ion importGalectin-3Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway via death domain receptorsGalectin-3Homo sapiens (human)
positive regulation of protein localization to plasma membraneGalectin-3Homo sapiens (human)
negative regulation of protein tyrosine phosphatase activityGalectin-3Homo sapiens (human)
negative regulation of immunological synapse formationGalectin-3Homo sapiens (human)
negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellGalectin-3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayGalectin-3Homo sapiens (human)
apoptotic processGalectin-7Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesGalectin-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
galactose bindingGalectin-9Homo sapiens (human)
enzyme bindingGalectin-9Homo sapiens (human)
carbohydrate bindingGalectin-9Homo sapiens (human)
disaccharide bindingGalectin-9Homo sapiens (human)
galactoside bindingGalectin-9Homo sapiens (human)
integrin bindingGalectin-8Homo sapiens (human)
protein bindingGalectin-8Homo sapiens (human)
carbohydrate bindingGalectin-8Homo sapiens (human)
RNA bindingGalectin-1Homo sapiens (human)
protein bindingGalectin-1Homo sapiens (human)
laminin bindingGalectin-1Homo sapiens (human)
lactose bindingGalectin-1Homo sapiens (human)
RNA bindingGalectin-3Homo sapiens (human)
protein phosphatase inhibitor activityGalectin-3Homo sapiens (human)
protein bindingGalectin-3Homo sapiens (human)
IgE bindingGalectin-3Homo sapiens (human)
protein phosphatase bindingGalectin-3Homo sapiens (human)
carbohydrate bindingGalectin-3Homo sapiens (human)
chemoattractant activityGalectin-3Homo sapiens (human)
laminin bindingGalectin-3Homo sapiens (human)
molecular condensate scaffold activityGalectin-3Homo sapiens (human)
disaccharide bindingGalectin-3Homo sapiens (human)
protein bindingGalectin-7Homo sapiens (human)
carbohydrate bindingGalectin-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
extracellular spaceGalectin-9Homo sapiens (human)
nucleusGalectin-9Homo sapiens (human)
cytoplasmGalectin-9Homo sapiens (human)
cytosolGalectin-9Homo sapiens (human)
collagen-containing extracellular matrixGalectin-9Homo sapiens (human)
nucleusGalectin-9Homo sapiens (human)
cytosolGalectin-9Homo sapiens (human)
extracellular spaceGalectin-8Homo sapiens (human)
cytoplasmGalectin-8Homo sapiens (human)
cytosolGalectin-8Homo sapiens (human)
membraneGalectin-8Homo sapiens (human)
cytoplasmic vesicleGalectin-8Homo sapiens (human)
cytoplasmGalectin-8Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular regionGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
cytoplasmGalectin-1Homo sapiens (human)
endoplasmic reticulum lumenGalectin-1Homo sapiens (human)
cytosolGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular exosomeGalectin-1Homo sapiens (human)
galectin complexGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
extracellular regionGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
nucleoplasmGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
mitochondrial inner membraneGalectin-3Homo sapiens (human)
cytosolGalectin-3Homo sapiens (human)
plasma membraneGalectin-3Homo sapiens (human)
cell surfaceGalectin-3Homo sapiens (human)
membraneGalectin-3Homo sapiens (human)
secretory granule membraneGalectin-3Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
extracellular exosomeGalectin-3Homo sapiens (human)
ficolin-1-rich granule membraneGalectin-3Homo sapiens (human)
spliceosomal complexGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
extracellular spaceGalectin-7Homo sapiens (human)
nucleusGalectin-7Homo sapiens (human)
cytoplasmGalectin-7Homo sapiens (human)
extracellular exosomeGalectin-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1884996Binding affinity to Pseudomonas aeruginosa LecA assessed as dissociation constant2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Small Carbohydrate Derivatives as Potent Antibiofilm Agents.
AID1181397Antagonist activity against human galectin 8 N-terminal domain by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID1181399Antagonist activity against human galectin 1 at 10 mM by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID1171663Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecA mutant assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1181394Antagonist activity against human galectin 1 by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID1373942Substrate activity at Escherichia coli Heptosyltransferase I assessed as ADP release at 100 uM using phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A.
AID383183Inhibition of Saccharomyces sp. alpha-glucosidase2008Journal of natural products, May, Volume: 71, Issue:5
alpha-Glucosidase inhibitory activity of triterpenoids from Cichorium intybus.
AID1857386Competitive binding affinity to recombinant Pseudomonas aeruginosa LecA expressed in Escherichia coli BL21(DE3) incubated for 30 to 60 mins by fluorescent polarization assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Lectin-Targeted Prodrugs Activated by
AID73825Tested for inhibition constant against glycogen phosphorylase b1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b.
AID1171664Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecB mutant assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1171655Binding affinity to Pseudomonas aeruginosa LecA by ITC method2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1171658Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecB mutant at 6 to 5000 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1171656Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 at 6 to 5000 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1171657Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 expressing deltalecA mutant at 6 to 5000 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1373943Inhibition of Escherichia coli Heptosyltransferase I assessed as reduction in ADP release at 1 mM using ODLA and ADP-heptose substrates in presence of phospho(enol)pyruvate and NADH by pyruvate kinase and LDH based ADP/NADH coupling assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A.
AID1181396Antagonist activity against human galectin 7 by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID1681526Inhibition of Pseudomonas aeruginosa ATCC 33347 LecA expressed in Escherichia coli BL21(DE3) cells incubated for 30 to 60 mins by (N-(fluorescein-5-yl)-N'-(beta-D-(m-aminophenyl)-galactopyranosyl)thiocarbamide) reporter based fluorescence polarization ass2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates Targeting Biofilm-Associated Lectins of
AID1181398Antagonist activity against human galectin 9 N-terminal domain by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID1171662Induction of bacterial aggregation in Pseudomonas aeruginosa PAO1 assessed as number of aggregates per 100 uL of PBS cell solution at 100 uM by optical microscopy2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
AID1181395Antagonist activity against human galectin 3 by fluorescence polarization assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2015Glycobiology, May, Volume: 25, Issue:5
Atomic-resolution structure of the α-galactosyl binding Lyophyllum decastes lectin reveals a new protein family found in both fungi and plants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's8 (44.44)29.6817
2010's6 (33.33)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.05 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]